Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$46.87 +0.1%	$48.20	$39.35 ▼ $63.33	$95.36B	0.38	12.99 million shs	47.28 million shs
ISRG Intuitive Surgical	$509.36 0.0%	$528.03	$413.82 ▼ $616.00	$182.56B	1.67	1.68 million shs	2.83 million shs
MDT Medtronic	$86.30 +0.7%	$84.49	$75.96 ▼ $96.25	$110.73B	0.79	6.91 million shs	13.08 million shs
SYK Stryker	$375.44 +0.6%	$374.95	$314.93 ▼ $406.19	$143.35B	0.91	1.33 million shs	2.01 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	0.00%	-5.71%	-0.26%	-23.25%	+14.84%
ISRG Intuitive Surgical	0.00%	-0.55%	-6.14%	+3.43%	+17.09%
MDT Medtronic	0.00%	-1.03%	+6.63%	-4.50%	+8.21%
SYK Stryker	0.00%	-0.42%	-0.76%	+1.09%	+7.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.9487 of 5 stars	3.2	5.0	4.2	4.0	3.5	3.3	1.3
ISRG Intuitive Surgical	4.7744 of 5 stars	3.4	5.0	0.0	4.0	3.0	2.5	1.9
MDT Medtronic	4.8806 of 5 stars	3.3	5.0	3.3	4.0	3.5	1.7	1.3
SYK Stryker	4.9089 of 5 stars	3.4	5.0	3.3	4.2	3.1	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.32	Hold	$58.00	23.75% Upside
ISRG Intuitive Surgical	2.70	Moderate Buy	$588.95	15.63% Upside
MDT Medtronic	2.67	Moderate Buy	$97.87	13.40% Upside
SYK Stryker	2.79	Moderate Buy	$427.30	13.81% Upside

Current Analyst Ratings Breakdown

Latest MDT, ISRG, BMY, and SYK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	MDT Medtronic	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/16/2025	MDT Medtronic	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$110.00
6/9/2025	ISRG Intuitive Surgical	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Sell	$515.00 ➝ $440.00
6/6/2025	MDT Medtronic	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/5/2025	ISRG Intuitive Surgical	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
5/22/2025	ISRG Intuitive Surgical	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$590.00 ➝ $650.00
5/22/2025	MDT Medtronic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$100.00 ➝ $98.00
5/22/2025	MDT Medtronic	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$105.00 ➝ $101.00
5/22/2025	MDT Medtronic	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$94.00 ➝ $92.00
5/22/2025	SYK Stryker	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$443.00 ➝ $455.00
5/19/2025	MDT Medtronic	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.30B	1.97	$5.89 per share	7.96	$8.08 per share	5.80
ISRG Intuitive Surgical	$8.35B	21.86	$7.99 per share	63.76	$46.41 per share	10.98
MDT Medtronic	$33.54B	3.30	$7.75 per share	11.14	$37.62 per share	2.29
SYK Stryker	$22.60B	6.34	$15.08 per share	24.90	$54.13 per share	6.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.55	7.70	1.39	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
ISRG Intuitive Surgical	$2.32B	$6.82	74.69	66.76	5.40	28.41%	14.43%	12.81%	7/17/2025 (Estimated)
MDT Medtronic	$4.66B	$3.62	23.84	14.80	2.33	13.90%	14.54%	7.83%	8/19/2025 (Estimated)
SYK Stryker	$2.99B	$7.40	50.73	25.32	2.83	12.31%	23.74%	11.25%	7/29/2025 (Estimated)

Latest MDT, ISRG, BMY, and SYK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/17/2025	Q2 2025	ISRG Intuitive Surgical	$1.92	N/A	N/A	N/A	$2.35 billion	N/A
5/21/2025	Q4 2025	MDT Medtronic	$1.58	$1.62	+$0.04	$0.82	$8.81 billion	$8.93 billion
5/1/2025	Q1 2025	SYK Stryker	$2.73	$2.84	+$0.11	$1.69	$5.68 billion	$5.87 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/22/2025	Q1 2025	ISRG Intuitive Surgical	$1.71	$1.81	+$0.10	$1.92	$2.19 billion	$2.25 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.29%	N/A	92.88%	17 Years
ISRG Intuitive Surgical	N/A	N/A	N/A	N/A	N/A
MDT Medtronic	$2.80	3.24%	N/A	77.35%	49 Years
SYK Stryker	$3.36	0.89%	N/A	45.41%	32 Years

Latest MDT, ISRG, BMY, and SYK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/8/2025	SYK Stryker	quarterly	$0.84	0.88%	6/30/2025	6/30/2025	7/31/2025
5/21/2025	MDT Medtronic	quarterly	$0.71	3.3%	6/27/2025	6/27/2025	7/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.65	1.28	1.17
ISRG Intuitive Surgical	N/A	4.98	3.97
MDT Medtronic	0.53	1.85	1.42
SYK Stryker	0.69	1.64	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
ISRG Intuitive Surgical	83.64%
MDT Medtronic	82.06%
SYK Stryker	77.09%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.07%
ISRG Intuitive Surgical	0.70%
MDT Medtronic	0.20%
SYK Stryker	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
ISRG Intuitive Surgical	15,638	358.42 million	355.91 million	Optionable
MDT Medtronic	95,000	1.28 billion	1.28 billion	Optionable
SYK Stryker	53,000	381.69 million	361.84 million	Optionable

MDT, ISRG, BMY, and SYK Headlines

Recent News About These Companies

Paradiem LLC Decreases Stake in Stryker Corporation (NYSE:SYK)

June 22 at 6:55 AM | marketbeat.com

Stryker Corporation (NYSE:SYK) Stock Holdings Lifted by Kentucky Retirement Systems

June 22 at 6:19 AM | marketbeat.com

Consolidated Investment Group LLC Buys 7,610 Shares of Stryker Corporation (NYSE:SYK)

June 22 at 6:08 AM | marketbeat.com

Running Oak Capital LLC Has $15.38 Million Stake in Stryker Corporation (NYSE:SYK)

June 22 at 5:05 AM | marketbeat.com

Cullinan Associates Inc. Grows Position in Stryker Corporation (NYSE:SYK)

June 22 at 5:05 AM | marketbeat.com

Stryker Corporation (NYSE:SYK) Shares Sold by World Equity Group Inc.

June 22 at 4:40 AM | marketbeat.com

PFG Investments LLC Sells 1,246 Shares of Stryker Corporation (NYSE:SYK)

June 22 at 4:23 AM | marketbeat.com

Stryker Corporation (NYSE:SYK) Shares Sold by Envestnet Portfolio Solutions Inc.

June 22 at 4:06 AM | marketbeat.com

Stryker Corporation (NYSE:SYK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

June 22 at 2:07 AM | marketbeat.com

Sivik Global Healthcare LLC Trims Stock Position in Stryker Corporation (NYSE:SYK)

June 21 at 7:43 AM | marketbeat.com

Fishman Jay A Ltd. MI Cuts Position in Stryker Corporation (NYSE:SYK)

June 21 at 7:31 AM | marketbeat.com

Suncoast Equity Management Increases Position in Stryker Corporation (NYSE:SYK)

June 21 at 6:51 AM | marketbeat.com

Praxis Investment Management Inc. Decreases Stake in Stryker Corporation (NYSE:SYK)

June 21 at 6:42 AM | marketbeat.com

Marietta Wealth Management LLC Makes New $4.58 Million Investment in Stryker Corporation (NYSE:SYK)

June 21 at 6:34 AM | marketbeat.com

Deltec Asset Management LLC Takes Position in Stryker Corporation (NYSE:SYK)

June 21 at 6:33 AM | marketbeat.com

GAM Holding AG Has $5.96 Million Stock Holdings in Stryker Corporation (NYSE:SYK)

June 21 at 6:24 AM | marketbeat.com

13,500 Shares in Stryker Corporation (NYSE:SYK) Bought by Covea Finance

June 21 at 5:30 AM | marketbeat.com

Segment Wealth Management LLC Buys 682 Shares of Stryker Corporation (NYSE:SYK)

June 20 at 7:27 AM | marketbeat.com

Stryker Corporation (NYSE:SYK) Shares Sold by ERn Financial LLC

June 19 at 7:41 AM | marketbeat.com

Stryker Corporation (NYSE:SYK) Shares Acquired by Norris Perne & French LLP MI

June 19 at 7:33 AM | marketbeat.com

Stryker council opposes state bill on property tax

June 18, 2025 | bryantimes.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Intuitive Surgical: Profit or Peril Ahead Amid Trade & Turf Wars?
By Leo Miller | June 19, 2025
View Intuitive Surgical: Profit or Peril Ahead Amid Trade & Turf Wars?

MDT, ISRG, BMY, and SYK Company Descriptions

Bristol Myers Squibb NYSE:BMY

$46.87 +0.03 (+0.06%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$46.93 +0.06 (+0.13%)

As of 06/20/2025 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Intuitive Surgical NASDAQ:ISRG

$509.36 -0.13 (-0.03%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$511.78 +2.43 (+0.48%)

As of 06/20/2025 07:59 PM Eastern

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Medtronic NYSE:MDT

$86.30 +0.57 (+0.66%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$86.96 +0.66 (+0.76%)

As of 06/20/2025 07:51 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Stryker NYSE:SYK

$375.44 +2.18 (+0.58%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$375.84 +0.41 (+0.11%)

As of 06/20/2025 06:43 PM Eastern

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time